chronic disease management – The Milli Chronicle

Friday, December 12, 2025

Latest:

Lululemon CEO exit sparks optimism for brand reset and renewed growth
US regulator grants initial approval for major crypto firms to launch national trust banks
Wall Street steadies as investors weigh inflation signals and long-term AI prospects
Mumbai Markets Rebound Strongly As Investor Confidence Rises Ahead of Key Inflation Data
Ozempic Debuts in India as Affordable Weekly Option for Growing Diabetes Care

Factual Version of a Story

Asia Featured News

NewsDesk Milli Chronicle December 12, 2025December 12, 2025 affordable semaglutide, chronic disease management, diabetes drug pricing, diabetes treatment India, glycemic control therapy, healthcare innovation India, heart health medication, India healthcare growth, India obesity care, Indian pharmaceutical market, kidney risk reduction drug, metabolic drug competition, metabolic health market, Novo Nordisk India, obesity treatment trends, Ozempic India launch, semaglutide generics, type 2 diabetes population, weekly diabetes injection, weight loss treatment India

Ozempic Debuts in India as Affordable Weekly Option for Growing Diabetes Care

Ozempic made its highly anticipated entry into the Indian market with pricing designed to improve access for millions managing type